865 related articles for article (PubMed ID: 27986466)
1. Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies.
Sunny NE; Bril F; Cusi K
Trends Endocrinol Metab; 2017 Apr; 28(4):250-260. PubMed ID: 27986466
[TBL] [Abstract][Full Text] [Related]
2. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Cusi K
Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
[TBL] [Abstract][Full Text] [Related]
3. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
4. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Ranjbar G; Mikhailidis DP; Sahebkar A
Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
[TBL] [Abstract][Full Text] [Related]
5. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities.
Gambino R; Musso G; Cassader M
Antioxid Redox Signal; 2011 Sep; 15(5):1325-65. PubMed ID: 20969475
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.
Ahmed A; Wong RJ; Harrison SA
Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2062-70. PubMed ID: 26226097
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic Fatty Liver Disease: Common Questions and Answers on Diagnosis and Management.
Westfall E; Jeske R; Bader AR
Am Fam Physician; 2020 Nov; 102(10):603-612. PubMed ID: 33179890
[TBL] [Abstract][Full Text] [Related]
8. Antioxidant Versus Pro-Apoptotic Effects of Mushroom-Enriched Diets on Mitochondria in Liver Disease.
Fontes A; Alemany-Pagès M; Oliveira PJ; Ramalho-Santos J; Zischka H; Azul AM
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31426291
[TBL] [Abstract][Full Text] [Related]
9. Neutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis.
Sun X; Seidman JS; Zhao P; Troutman TD; Spann NJ; Que X; Zhou F; Liao Z; Pasillas M; Yang X; Magida JA; Kisseleva T; Brenner DA; Downes M; Evans RM; Saltiel AR; Tsimikas S; Glass CK; Witztum JL
Cell Metab; 2020 Jan; 31(1):189-206.e8. PubMed ID: 31761566
[TBL] [Abstract][Full Text] [Related]
10. Current Options and Future Directions for NAFLD and NASH Treatment.
Zhang C; Yang M
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299189
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis and non-alcoholic fatty liver diseases.
Kanda T; Matsuoka S; Yamazaki M; Shibata T; Nirei K; Takahashi H; Kaneko T; Fujisawa M; Higuchi T; Nakamura H; Matsumoto N; Yamagami H; Ogawa M; Imazu H; Kuroda K; Moriyama M
World J Gastroenterol; 2018 Jul; 24(25):2661-2672. PubMed ID: 29991872
[TBL] [Abstract][Full Text] [Related]
12. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.
Stein LL; Dong MH; Loomba R
Adv Ther; 2009 Oct; 26(10):893-907. PubMed ID: 19921118
[TBL] [Abstract][Full Text] [Related]
13. Therapies in non-alcoholic steatohepatitis (NASH).
Oseini AM; Sanyal AJ
Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological management of nonalcoholic fatty liver disease.
Barb D; Portillo-Sanchez P; Cusi K
Metabolism; 2016 Aug; 65(8):1183-95. PubMed ID: 27301803
[TBL] [Abstract][Full Text] [Related]
15. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
16. Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option.
Dhir G; Cusi K
J Investig Med; 2018 Jan; 66(1):7-10. PubMed ID: 28918389
[TBL] [Abstract][Full Text] [Related]
17. The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation.
Chung HK; Kim YK; Park JH; Ryu MJ; Chang JY; Hwang JH; Lee CH; Kim SH; Kim HJ; Kweon GR; Kim KS; Shong M
Liver Int; 2015 Apr; 35(4):1341-53. PubMed ID: 25443620
[TBL] [Abstract][Full Text] [Related]
18. The common marmoset as a model for the study of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Kramer JA; Grindley J; Crowell AM; Makaron L; Kohli R; Kirby M; Mansfield KG; Wachtman LM
Vet Pathol; 2015 Mar; 52(2):404-13. PubMed ID: 24913270
[TBL] [Abstract][Full Text] [Related]
19. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
20. Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity.
Patterson RE; Kalavalapalli S; Williams CM; Nautiyal M; Mathew JT; Martinez J; Reinhard MK; McDougall DJ; Rocca JR; Yost RA; Cusi K; Garrett TJ; Sunny NE
Am J Physiol Endocrinol Metab; 2016 Apr; 310(7):E484-94. PubMed ID: 26814015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
